InVitae Stock Forecast, Price & News

InVitae's stock was trading at $15.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NVTA shares have increased by 169.5% and is now trading at $42.71.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InVitae in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for InVitae.

InVitae is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for InVitae.

InVitae Corp (NYSE:NVTA) issued its earnings results on Tuesday, August, 4th. The medical research company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by $0.15. The medical research company earned $46.20 million during the quarter, compared to the consensus estimate of $39.63 million. InVitae had a negative net margin of 182.73% and a negative return on equity of 77.82%. InVitae's quarterly revenue was down 14.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.54) EPS.
View InVitae's earnings history.

6 Wall Street analysts have issued 12 month target prices for InVitae's shares. Their forecasts range from $20.00 to $38.00. On average, they anticipate InVitae's share price to reach $33.54 in the next year. This suggests that the stock has a possible downside of 21.5%.
View analysts' price targets for InVitae.

Some companies that are related to InVitae include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Guardant Health (GH), Natera (NTRA), ELEKTA AB/ADR (EKTAY), Burning Rock Biotech (BNR), Veracyte (VCYT), CareDx (CDNA), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Genetron (GTH), RadNet (RDNT), Personalis (PSNL), ALX Oncology (RNLX) and Progenity (PROG).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other InVitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), salesforce.com (CRM), Alibaba Group (BABA), Shopify (SHOP), Trade Desk (TTD), Tesla (TSLA), Advanced Micro Devices (AMD) and Walt Disney (DIS).

(NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

InVitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

InVitae's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (9.79%), Gilder Gagnon Howe & Co. LLC (5.53%), Vanguard Group Inc. (4.76%), Macquarie Group Ltd. (3.01%), Bank of New York Mellon Corp (1.15%) and Victory Capital Management Inc. (0.83%). Company insiders that own InVitae stock include E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Katherine Stueland, Patty Dumond, Randal W Scott, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer and Thomas Brida.
View institutional ownership trends for InVitae.

NVTA stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Russell Investments Group Ltd., Principal Financial Group Inc., Principal Financial Group Inc., Goldman Sachs Group Inc., Advisor Group Holdings Inc., PNC Financial Services Group Inc., and Profit Investment Management LLC. Company insiders that have sold InVitae company stock in the last year include E Lee Bendekgey, Eric Aguiar, Katherine Stueland, Robert F Werner, Robert L Nussbaum, Sean E George, Shelly D Guyer, and Thomas Brida.
View insider buying and selling activity for InVitae.

NVTA stock was purchased by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Vanguard Group Inc., Canada Pension Plan Investment Board, Gilder Gagnon Howe & Co. LLC, Victory Capital Management Inc., Driehaus Capital Management LLC, Man Group plc, and Charles Schwab Investment Management Inc..
View insider buying and selling activity for InVitae.

Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVTA stock can currently be purchased for approximately $42.71.

InVitae has a market capitalization of $5.63 billion and generates $216.82 million in revenue each year. The medical research company earns $-241,960,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. InVitae employs 1,300 workers across the globe.

The official website for InVitae is www.invitae.com.

InVitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The medical research company can be reached via phone at 415-374-7782 or via email at [email protected]